Acquisition advances Labcorp's specialty testing strategy in key areas such as oncology and rare diseasesKey milestone reached in Invitae's Chapter 11 processBURLINGTON, N.C. and SAN FRANCISCO, May 7, 2024
Labcorp beats Q1 sales estimates, driven by organic growth and acquisitions. Revised 2024 guidance projects higher EPS and sales growth. The acquisition of Invitae is expected to bolster Labcorp's specialty testing capabilities.
Labcorp acquires certain operations of Opko Health subsidiary BioReference Health. The assets Labcorp is acquiring generate about $100 million in annual revenue, with the transaction valued at $237.5 million.
Transaction to enhance Labcorp's laboratory services network and expand access to the company's high-quality clinical laboratory servicesBURLINGTON, N.C. and MIAMI, March 28, 2024 /PRNewswire/
A less invasive alternative to PET scans, these tests offer quick identification for emerging treatments. Learn more about the latest advancements in Alzheimer's detection.